Stock Analiz

Stereotaxis, Inc. STXS

Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026

$0.84Market cap $84M
Open the interactive analysis →

Stereotaxis, Inc. (STXS) is a healthcare company listed in the US with a market value of about $84M. In the twelve months to June 30, 2026 it had revenue of $30M and net income of -$22M, a net margin of -74.2%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -81%.

About Stereotaxis

Stereotaxis is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus. Revenue went from $35M in 2014 to $32M in 2025, a decline of about 0.7% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 20% over three years (dilution for shareholders). It spends 29% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.8
P/B6.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-18.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)20.3%
Revenue growth (5 yrs, per year)4.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-65.8%
ROIC (5-yr avg.)-80.9%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$30M$32M$27M$27M$28M$35M$27M$29M$29M$31M$32M
Net income-$22M-$22M-$24M-$21M-$18M-$11M-$7M-$5M$116756-$6M-$5M
Free cash flow-$16M-$14M-$9M-$10M-$11M-$4M-$4M-$5M-$3M-$5M-$7M
EPS (diluted)$-0.24$-0.25$-0.30$-0.27$-0.26$-0.16$-0.11$-0.10$-0.03$-0.32$-0.54
Net margin-74.2%-66.8%-89.3%-77.4%-65.0%-30.6%-25.0%-15.9%0.4%-18.9%-16.4%
ROIC—-92.3%-161.7%-79.0%-46.1%-25.5%-13.6%-14.1%-148.0%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Stereotaxis pay a dividend?

Not currently.

Is Stereotaxis a good stock to buy?

We do not give buy or sell advice. Stereotaxis scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.